glp-1 news today Can one drug do it all? Reviewing the expanding clinical universe of agonists FDA warns Novo Nordisk of
Description
Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial
In a 2023 case report, a 31-year-old appropriately fasted female on Ozempic was found to have significant amounts of solid food in her stomach during endoscopy
Worsening metabolic disease from regain increases healthcare utilization, medication costs for diabetes and cardiovascular conditions, and potential surgical interventions
Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascularrisk in type 2 diabetes mellitus
Nature 404 , 661671, (2000)
At 8mg, the glucagon receptor stimulation is strong enough to produce the tingling and altered skin sensitivity reported in trials
